Lipella Pharmaceuticals Inc. (LIPO)
| Market Cap | 2.31K -99.9% |
| Revenue (ttm) | 389.78K -19.4% |
| Net Income | -5.33M |
| EPS | -1.76 |
| Shares Out | 4.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 310 |
| Open | 0.0005 |
| Previous Close | 0.0005 |
| Day's Range | 0.0005 - 0.0005 |
| 52-Week Range | 0.0002 - 0.6280 |
| Beta | 1.89 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 22, 2026 |
About Lipella Pharmaceuticals
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobul... [Read more]
Financial Performance
In 2024, Lipella Pharmaceuticals's revenue was $536,357, an increase of 19.29% compared to the previous year's $449,617. Losses were -$5.02 million, 8.60% more than in 2023.
Financial StatementsNews
Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11
PITTSBURGH, March 30, 2026 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today that it filed a voluntary petition for...
Lipella Pharmaceuticals Quarterly report: Q3 2025
Lipella Pharmaceuticals has published its Q3 2025 quarterly earnings report on November 14, 2025.
Lipella Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum 2025
Proprietary liposomal technology enables targeted delivery for mucosal diseases, with LP-10 oral rinse showing strong safety and efficacy in phase two OLP trials. Addressing a significant unmet need, LP-10 targets a $750M peak sales opportunity, with next steps including a placebo-controlled trial and industry partnership.
Lipella Pharmaceuticals announces final results from Phase 2a study of LP-10
Lipella Pharmaceuticals (LIPO) announced final results from its completed Phase 2a multicenter, dose-ranging study evaluating LP-10, a proprietary liposomal tacrolimus oral rinse, in patients with sym...
Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus
PITTSBURGH , Sept. 15, 2025 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (OTC: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company transforming care with innovative mucosal deli...
Lipella Pharmaceuticals Quarterly report: Q2 2025
Lipella Pharmaceuticals has published its Q2 2025 quarterly earnings report on August 14, 2025.
Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting
PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases...
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market
PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases...
Lipella Pharmaceuticals announces U.S. patent issuance for diagnostic tech
Lipella Pharmaceuticals (LIPO) announced the issuance of U.S. Patent No. 12,326,492, titled “Systems and Methods of Detecting Interstitial Cystitis.” The patent was issued by the United States Patent ...
Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology
PITTSBURGH, June 17, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for disea...
Lipella Pharmaceuticals Proxy statement: Proxy Filing
Lipella Pharmaceuticals filed a proxy statement on June 10, 2025, providing details for shareholder voting and corporate governance matters.
Lipella Pharmaceuticals re-signs manufacturing collab with Cook MyoSite
Lipella Pharmaceuticals (LIPO) announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite to support Chemistry, Manufacturing and Control, CMC, documentation supportin...
Lipella Pharmaceuticals to present Phase 2a data for LP-310
Lipella Pharmaceuticals (LIPO) announced that topline data from the first two dose cohorts of its ongoing Phase 2a trial of LP-310 for the treatment of Oral Lichen Planus will be…
Lipella Pharmaceuticals Quarterly report: Q1 2025
Lipella Pharmaceuticals has published its Q1 2025 quarterly earnings report on May 13, 2025.
Lipella abstract on LP-10 for OLP accepted for presentation at AAOM, EAOM
Lipella Pharmaceuticals (LIPO) announced that its abstract on LP-10 for the treatment of Oral Lichen Planus, OLP, has been accepted for podium presentation at the 2025 joint international meeting of…
Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”
Joint meeting to be held in Las Vegas, May 14-17 Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute Topline study results demonstrate clinically meaningful improvements i...
Lipella Pharmaceuticals announces results from second cohort of LP-310 trial
Lipella Pharmaceuticals (LIPO) announced topline results from the second cohort of its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal-tacrolimus oral rinse formulation of LP-1...
Lipella Pharmaceuticals completes enrollment in LP-310 trial
Lipella Pharmaceuticals (LIPO) announced the completion of enrollment in its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal tacrolimus oral rinse for the treatment of oral lic...
Lipella Pharmaceuticals Registration statement: Registration Filing
Lipella Pharmaceuticals filed a registration statement on March 28, 2025, providing details about a securities offering with the SEC.
Lipella Pharmaceuticals files to sell 5.62M shares of common stock for holders
06:25 EDT Lipella Pharmaceuticals (LIPO) files to sell 5.62M shares of common stock for holders
Lipella Pharmaceuticals Annual report: Q4 2024
Lipella Pharmaceuticals has published its Q4 2024 annual report on March 27, 2025.
Spartan Capital Securities, LLC Announces Key February Transactions
New York, NY, March 07, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a full-service investment banking firm, is pleased to announce a series of strategic transactions completed in Februar...
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement
New York, NY, March 04, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of a $3,788,000 private placement ...
Morning Movers: Lattice Semiconductor, SelectQuote jump after earnings reports
Check out this morning’s top movers from around Wall Street, compiled by The Fly. HIGHER – Lipella Pharmaceuticals (LIPO) up 50% after reporting “positive” results from its Phase 2a LP-310…
Lipella Pharmaceuticals reports ‘positive’ results from Phase 2a LP-310 trial
Lipella Pharmaceuticals (LIPO) shared topline analysis of its Phase 2a multicenter dose-ranging trial examining LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 being developed to treat ...